Margetuximab-cmkb
Margetuximab-cmkb works by binding to HER2, a protein found in high levels on some cancer cells and causes them to grow. Margetuximab-cmkb blocks the activity of HER2 and triggers a type of immune reaction that kills cells that have a lot of HER2. It is a type of targeted therapy drug called a monoclonal antibody.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Margetuximab-cmkb is approved to be used with chemotherapy to treat:
- breast cancer that is HER2 positive (HER2+) and has metastasized (spread to other parts of the body). It is used in adults who have received two or more anti-HER2 treatments, including at least one for metastatic disease.
Margetuximab-cmkb is also being studied in the treatment of other types of cancer.
More About Margetuximab-cmkb
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Margetuximab-cmkb - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Margetuximab-cmkb - Check for trials from NCI's list of cancer clinical trials now accepting patients.